Message #26 From:
NewsBot Date: March 8, 2007 05:15:00 AM
ABPI News Accentia Biopharmaceuticals Continues Nationwide Education Initiative to Promote Better Understanding of Chronic Sinusitis
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals (NASDAQ:ABPI) -- Television stations across the country recently interviewed Dr. David Sherris, co-inventor of SinuNase™ and Chairman of the University of Buffalo Department of Otolaryngology, about the diagnosis and treatment of chronic sinusitis, and the extensive research conducted at the Mayo Clinic that identified a fungal origin of the disease. These interviews are part of Accentia’s ongoing public education program to address the extensive research that has shown a fungal etiology related to chronic sinusitis, a disease that affects over 31 million Americans, and the proposed approach to treat the disease with a very low dose of an antifungal in an intranasal formulation.
To request a complimentary CD of the aired interviews please visit Accentia’s website at www.accentia.net. Those interested are asked to submit their request by visiting the “Investors” section of the website, selecting “Contacts & Info Requests”, and clicking “Chronic Sinusitis Education Media CD”, along with entering all contact information. To confirm the request, select “Submit” once complete.
The Company has received Fast Track status from the Food and Drug Administration for SinuNase, a unique formulation of low-dose intranasal amphotericin B, and has initiated a Phase 3 clinical trial at sites across the U.S with patients that have severe chronic sinusitis who have had one or more prior sinus surgeries. Despite the fact that there are an estimated 31 million affected U.S. patients, and that chronic sinusitis is by far the most common chronic respiratory disease with a market approximately twice the size of asthma, there is currently no approved prescription pharmaceutical available. If approved, SinuNase will be the first therapy available to treat sufferers of chronic sinusitis.
Patients who believe they may be eligible to participate in a clinical trial with SinuNase are encouraged to visit www.accentia.net/patients/trials_sinunase.php, or call 212-686-4100.
About Accentia Biopharmaceuticals, Inc.
Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of late-stage "disruptive" clinical products, especially for already-approved drugs in new formulations and/or new indications that are patent-protected and which represent new therapeutics with greater clinical and economic value. Accentia has a pipeline of products in late-stage clinical development. The company's lead respiratory product candidate is SinuNase(TM), which is under clinical development to treat chronic sinusitis (rhinosinusitis). SinuNase is a novel application and formulation of a known anti-fungal exclusively licensed from the Mayo Foundation for Medical Education and Research. The product has been Fast Tracked by the FDA and the Company has commenced a Phase 3 clinical trial. The Company's other lead product is BiovaxID(TM), a patient-specific anti-cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma. BiovaxID, which is being developed by Accentia's subsidiary, Biovest International, Inc., (OTCBB: BVTI), is currently in a Fast-Tracked Phase 3 clinical trial. The Company is also proposing to enter a Phase 3 clinical trial for Multiple Sclerosis using Revimmune™, which uses an approved drug in an exclusively licensed method of therapy to “reboot” a patient’s immune system. Revimmune was developed at the Johns Hopkins School of Medicine for the elimination of autoimmunity, and Accentia has acquired the exclusive worldwide rights for all autoimmune diseases. For further information, please visit www.accentia.net.
Forward-Looking Statements
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about SinuNase, BiovaxID, AutovaxID, Revimmune and any other statements relating to products, product candidates, product development programs the FDA or clinical trial process including the commencement, process or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Accentia to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Accentia undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
